152 related articles for article (PubMed ID: 29411964)
41. A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment.
Yuan X; Ji W; Chen S; Bao Y; Tan S; Lu S; Wu K; Chu Q
Int J Nanomedicine; 2016; 11():2119-31. PubMed ID: 27307727
[TBL] [Abstract][Full Text] [Related]
42. Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy.
Gu Y; Zhong Y; Meng F; Cheng R; Deng C; Zhong Z
Biomacromolecules; 2013 Aug; 14(8):2772-80. PubMed ID: 23777504
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
[TBL] [Abstract][Full Text] [Related]
44. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
45. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
46. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
[TBL] [Abstract][Full Text] [Related]
47. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
Baek JS; Cho CW
Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
[TBL] [Abstract][Full Text] [Related]
48. Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression.
Xu B; Xia S; Wang F; Jin Q; Yu T; He L; Chen Y; Liu Y; Li S; Tan X; Ren K; Yao S; Zeng J; Song X
Mol Pharm; 2016 Feb; 13(2):663-76. PubMed ID: 26695934
[TBL] [Abstract][Full Text] [Related]
49. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy.
Ruttala HB; Ko YT
Colloids Surf B Biointerfaces; 2015 Apr; 128():419-426. PubMed ID: 25797481
[TBL] [Abstract][Full Text] [Related]
50. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
[TBL] [Abstract][Full Text] [Related]
51. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W
J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115
[TBL] [Abstract][Full Text] [Related]
52. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
53. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
54. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
55. Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer.
Xiao W; Suby N; Xiao K; Lin TY; Al Awwad N; Lam KS; Li Y
J Control Release; 2017 Oct; 264():169-179. PubMed ID: 28847739
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system.
Zhang Q; Ran R; Zhang L; Liu Y; Mei L; Zhang Z; Gao H; He Q
J Control Release; 2015 Jan; 197():208-18. PubMed ID: 25445692
[TBL] [Abstract][Full Text] [Related]
57. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
Parayath NN; Gandham SK; Leslie F; Amiji MM
Cancer Lett; 2019 Oct; 461():1-9. PubMed ID: 31288064
[TBL] [Abstract][Full Text] [Related]
58. Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
Ajorlou E; Khosroushahi AY; Yeganeh H
Pharm Res; 2016 Jun; 33(6):1426-39. PubMed ID: 26908046
[TBL] [Abstract][Full Text] [Related]
59. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
60. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
